Treatment of primary Sjogren syndrome: A systematic review. In primary Sjögren syndrome, evidence from controlled trials suggests benefits for pilocarpine and cevimeline for sicca features and topical cyclosporine for moderate or severe dry eye. Anti–tumor necrosis factor agents have not shown clinical efficacy, and larger controlled trials are needed to establish the efficacy of rituximab. Manuel Ramos-Casals, MD, PhD. JAMA. 2010;304(4):452-460. (Also see: Treatments for Sjogren Syndrome)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant News Guide
International Scleroderma Network(ISN)
Treatment of primary Sjogren syndrome: A systematic review
No replies to this topic